A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
← catalyst calendarNCT07728097 · readout in 861 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Research UK Limited.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-11-18 | estimated | When the study began enrolling |
| Primary completion | 2028-12-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lennox-Gastaut Syndrome
Intervention
- Drug: Cannabidiol Oral Solution — also filed as JZP926, CBD-OS, Epidiolex, Epidyolex
Primary outcome
what the primary-completion date above is the date OFPercentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequency
measured End of Treatment Period, Week 24
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed